The purpose of this legislation is to enhance transparency in the process of applying for generic drugs. It aims to provide clearer information about how generic drugs compare to their brand-name counterparts, ensuring that applicants understand the requirements and standards for approval. Key provisions of the legislation include a requirement for the Secretary of Health and Human Services to inform applicants whether their generic drug is qualitatively and quantitatively the same as the brand-name drug they are referencing.